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Abstract: Natural killer (NK) cells are innate lymphoid cells that play a pivotal role in tumor
surveillance. Exosomes are nanovesicles released into the extracellular environment via the
endosomal vesicle pathway and represent an important mode of intercellular communication.
The ability of anticancer chemotherapy to enhance the immunogenic potential of malignant
cells mainly relies on the establishment of the immunogenic cell death (ICD) and the release of
damage-associated molecular patterns (DAMPs). Moreover, the activation of the DNA damage
response (DDR) and the induction of senescence represent two crucial modalities aimed at promoting
the clearance of drug-treated tumor cells by NK cells. Emerging evidence has shown that stress
stimuli provoke an increased release of exosome secretion. Remarkably, tumor-derived exosomes
(Tex) produced in response to stress carry distinct type of DAMPs that activate innate immune cell
populations. Moreover, stress-induced ligands for the activating receptor NKG2D are transported
by this class of nanovesicles. Here, we will discuss how Tex interact with NK cells and provide
insight into their potential role in response to chemotherapy-induced stress stimuli. The capability of
some “danger signals” carried by exosomes that indirectly affect the NK cell activity in the tumor
microenvironment will be also addressed.
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1. Introduction
Cellular cross-talk is a crucial event in multicellular organisms, where cells can communicate
with each other through direct cell–cell contact or through the release of soluble factors. Exosomes
are nanovesicles released into the extracellular environment via the endosomal vesicle pathway
by fusion with the plasma membrane and are essential for intercellular communication [1]. In the
tumor microenvironment, the content of cancer-secreted exosomes can be transferred not only to the
neoplastic cells but also to different type of immune cells, thus modulating the anti-tumor immune
response and affecting tumor progression [2].
Natural killer (NK) cells are innate lymphoid cells [3] that play a pivotal role in tumor surveillance
through both the direct killing of cancer cells and cytokine production [4]. NK cell activation is
tightly regulated by a delicate balance between activating and inhibitory signals, with the latter being
primarily transduced by receptors for Major Histocompatibility Complex (MHC) class I molecules
(KIRs, CD94/NKG2A). Recognition of induced self on tumor cells triggers a number of non-MHC
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class I–restricted activating receptors, such as NK group 2D (NKG2D), DNAX accessory molecule-1
(DNAM-1/CD226), and the natural cytotoxicity receptors (NCRs) [5]. Moreover, NK cells can mediate
target cell death through the surface expression of death inducing ligands belonging to the tumor
necrosis factor (TNF) family, such as Fas ligand (FasL) and TNF-related apoptosis inducing ligand
(TRAIL).
The role of tumor-derived exosomes (Tex) on the modulation of NK cell-mediated functions is
still a matter of debate and seems to be dependent on the molecular cargo and the source of these
vesicles [6].
The failure of antitumor immunity is often due to low immunogenicity of cancer cell variants or to
the aptitude of neoplastic cells to induce immunosuppression. The fulfillment of anticancer therapies
to enhance the immunogenic potential of malignant cells is based on different mechanisms, including
the activation of the DNA damage response (DDR) and the induction of senescence as two crucial
modalities promoting the clearance of drug-treated tumor cells by NK cells. In this context, low doses
of chemotherapeutic drugs have been shown to induce immunogenic senescence and stimulate NK
cell-mediated recognition and clearance of drug-treated tumor cells via the upregulation of NKG2D
and DNAM-1 activating ligands on the surface of cancer cells [7–11]. In addition, the establishment of
the immunogenic cell death (ICD) and the release of damage-associated molecular patterns (DAMPs)
represent another important approach to strengthen the efficacy of immunotherapy [12]. DAMPs are
endogenous molecules harbored intracellularly in normal conditions, but they can be exposed on the
tumor cell surface or released upon stress, injury, or cell death, thereby becoming able to bind to cognate
receptors on immune cells [13–15]. Thus, DAMPs can directly activate innate immune cells, such as the
Dendritic cells (DCs), macrophages, neutrophils and NK cells, and indirectly stimulate the adaptive T
cell responses by promoting maturation of DCs and tumor antigen processing and presentation.
Emerging evidence has shown the presence of different types of DAMPs in exosomes, including
molecules belonging to the heat shock protein (HSP) family [16–18], and the high-mobility group box
1 (HMGB1) [19,20], but also dsDNA [21,22] and RNA [23], all of which are able to engage distinct
pattern recognition receptors (PRRs). Of interest, stress-induced ligands for the NKG2D activating
receptor have also been reported to be associated with exosomes [24,25].
Herein, we will discuss how cancer-derived exosomes contribute to regulate the NK cell-mediated
functions in response to chemotherapeutic treatment, as well as in the presence of stress stimuli
focusing on: (i) the modulation of exosome release from cancer cells under stress conditions; and
(ii) the stress-induced molecules associated with cancer-derived exosomes, such as DAMPs and
NKG2D ligands.
2. Exosomes, General Features
Extracellular vesicles (EVs) are a heterogeneous group of bilayer membrane particles that can
be classified into three subtypes according to the cellular compartment they originate from and their
size. Specifically, apoptotic bodies having a size falling in the range of 1000–5000 nm represent the
largest class of vesicles and are generated during apoptotic cell death; microvesicles or ectosomes
(200–1000 nm) originate through the budding of the plasma membrane; and, finally, the exosomes
representing the smallest type of EVs are characterized by a size ranging between 30–150 nm and are
formed in the late endosomal compartment [26].
The present review focuses mainly on exosomes that contain proteins, nucleic acids (DNA, mRNA
and miRNAs), lipids and metabolites. These nanovesicles, initially considered only a way to expel
cellular garbage, have generate significant interest in recent decades because of their ability to carry
and “protect” biologically active molecules in the extracellular environment and to transfer them to
target cells. Exosomes are released from almost all cell types under both physiological and pathological
conditions, such as cancer. In this condition, tumor exosomes (Tex) can interact and be taken up by
cancer cells themselves or by other cells present in the tumor microenvironment or distant from the
tumor site, causing different effects. In fact, they are able to modulate tumor-induced immune response,
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angiogenesis, tumor progression, and premetastatic niche formation in an autocrine, paracrine or
endocrine manner thanks to their ability to move throughout the body fluids [27,28].
From a biochemical point of view, exosomes are structurally composed by a lipid bilayer
membrane enriched in cholesterol, phosphatidylserine, sphingomyelin, ceramide, sphingolipids and a
low amount of phosphatidylcholine [29]. Moreover, these nanovesicles typically express enriched sets
of proteins that comprise some members of the tetraspanin family (i.e., CD9, CD63, CD81), adhesion
molecules, cytoskeleton components, endosomal sorting complexes required for transport (ESCRT
complex) (TSG101, ALIX), HSPs, annexins and Rab proteins. Interestingly, several studies have shown
that the majority of exosomal proteins are loaded through various sorting mechanisms. For example,
post-translational modifications, including monoubiquitylation, glycosylation, sumoylation, oxidation
and phosphorylation, regulate the exosomal cargo targeting the proteins into the multivesicular
bodies [30]. The enrichment of specific proteins into exosomes is also strongly dependent on the origin
of the parental cell. Emerging evidence has shown that exosome composition, as well as biogenesis and
secretion, can be affected by external stimuli, including stress conditions such as heat shock, oxidative
stress, chemotherapy, irradiation, hypoxia, and hypothermia.
3. Modulation of Tex Release in Response to Stress Stimuli
A number of studies have shown that different stress conditions provoke increased exosome
release from cancer cells. Interestingly, thermal and oxidative stress enhance the exosome secretion
from leukemia/lymphoma T and B cell lines [31] and hypoxic conditions have been shown to be
effective to enhance Tex release from breast cancer cells [32]. In addition, sublethal doses of various
chemotherapeutic agents, including genotoxic drugs and proteasome inhibitors, stimulate exosome
secretion in different tumor models. As such, multiple myeloma cells released an augmented number of
nanovescicles upon melphalan [33,34] or bortezomib treatment [34]. Similarly, 5-fluorouracil, cisplatin
and doxorubicin induced an increase in the amount of HSP70+ exosomes from melanoma and colon
cancer cell lines [35]. Interestingly, these authors further proved that cisplatin treatment of mice-bearing
tumors determined a huge increase of exosomes in the blood of drug-treated mice [35]. A recent study
indicated that heat stress increased the quantity of doxorubicin-containing exosomes from tumor cells,
and enhanced the anti-tumor effect of exosomes from the doxorubicin-treated tumor cells, suggesting
new strategies for cancer therapy by the combined use of chemotherapy and hyperthermia [36].
Mechanisms behind the stress-induced exosome secretion are still largely unknown, although the
contribution of the tumor-suppressor gene p53 has been described in different models. In this regard,
Lehmann and coworkers have shown that irradiation of prostate cancer cells induced an augmented
secretion of exosome-like vesicles with a mechanism mediated by p53 activation [37]. In addition,
a p53-regulated gene product, the tumor suppressor activated pathway 6 (TSAP6), was shown to
enhance exosome production in cells undergoing a p53 response to stress [38]. In line with these
observations, exosome secretion was reported to be severely compromised in TSAP6-null mice [39].
Several studies have shown that increased exosome secretion in cancer cells can be associated to a
senescent phenotype [37,40].
4. Tex as Carriers of Stress-Induced Molecules and DAMPs
As already mentioned, exosomes are released from cancer cells in the tumor microenvironment
and their content can be transferred not only to the neoplastic cells but also to cells of the immune
system. The exosome uptake can be mediated by various mechanisms such as protein–protein
interaction, passive fusion with the plasma membrane through lipid–lipid interaction, and endocytosis,
and they differ depending on the recipient cell [41,42]. Various molecules have been described to be
involved in the interaction between exosomes and target cells, including integrins, immunoglobulins,
proteoglycans and lectins, and these interactions appear to facilitate the endocytosis process and
are important to define the selectivity of target cells [43]. Hwang and colleagues have shown
that Intercellular adhesion molecule 1/Lymphocyte antigen-associated antigen-1 (ICAM-1/LFA-1)
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interactions are involved in the DC-derived exosome uptake by T lymphocytes [44]. A number
of studies have described that Tex can be taken up by all leukocyte subpopulations, including
NK cells, but the mechanisms behind this process are still largely unknown [45]. Our group has
recently found that multiple myeloma-derived exosomes are taken up by human primary NK cells
through a mechanism mainly dependent on endocytic routes requiring dynamin and caveolae/raft
endocytosis [33]. The source of exosomes can strongly affect the efficiency of NK cell uptake as shown
by the usage of exosomes derived from distinct cancer cell lines [46].
In the following sections, we will illustrate the role of some molecules acting as “danger signals”,
as well as the stress-induced NKG2D ligands associated to Tex in the modulation of NK-cell mediated
functions. The capability of some danger signals carried by exosomes that indirectly affect the NK cell
activity in the tumor microenvironment will be also discussed.
4.1. NKG2D Ligands
The activating receptor NKG2D is a C-type lectin-like receptor expressed on NK cells, γδ T
cells, CD8+ T cells, and a subset of CD4+ T cells, and represents a major recognition receptor for the
detection and elimination of transformed cells. Engagement of NKG2D by its ligands on target cells
triggers cytotoxicity and cytokine production. NKG2D ligands belong to the Retinoic Acid Early
Inducible-1 gene, RAE (α−ε), H60 (a–c) and murine UL16-binding protein-like transcript, MULT1
families in mice and to the MHC-related genes, MIC (MICA and MICB) and UL16 binding proteins,
ULBP (ULBP1–ULBP6) families in humans [47]. These molecules are generally absent in healthy
cells, but are instead expressed on different type of cancer cells and can be induced or upregulated in
response to an ample variety of stress stimuli [48]. In this regard, treatment of cancer cells with distinct
classes of therapeutic drugs, such as genotoxic agents [7,49], histone deacetylase inhibitors [50,51],
and proteasome inhibitors [52], upregulate NKG2D ligands on the surface of cancer cells favoring their
NK cell recognition and killing [53]. NKG2D ligands can be released in the extracellular milieu through
protease-mediated cleavage or associated with exosomes [54]. The choice of one of these processes
is mainly dependent on the ligand type, as well as its allelic variant [55–58]. Recently, a number of
studies have shown that NKG2D ligands from both MICA/B and ULBP families are expressed on
the surface of exosome-like vesicles released from ovarian cancer [59], melanoma [60], and prostate
cancer cells [61]. Remarkably, NKG2D ligands such as ULBP3 and ULBP1 [57], or the allelic variant
MICA*008 [58], are secreted exclusively by exosomes.
As already mentioned, NKG2D ligand expression on the surface of cancer cells increases in
response to stress stimuli, and as a consequence the amount of these molecules in exosomes could
also be augmented. In line with these considerations, Hedlund and colleagues have shown that
oxidative stress enhances the release of NKG2D ligand-bearing exosomes from cancer cell lines [31].
Differently from the metalloprotease-mediated shedding [49,62–64], it is still unclear whether the
release of NKG2D ligands via exosomes also results in the reduction of their surface expression on
cancer cells.
It is likely that the expression of NKG2D ligands on the surface of tumor exosomes should
preserve their biological activity by keeping the whole-molecule and the three-dimensional protein
structure. It has been reported in different cellular models that exosomes expressing NKG2D ligands
induced NKG2D downregulation in NK and CD8+ T cells leading to impaired cytotoxic function
in vitro [58,59,61,65]. Of interest, although the NKG2D ligands associated with Tex down-regulate the
cognate receptor, the constitutive levels of granzyme B and perforin in both cytotoxic T and NK cells
are preserved [65]. On the other hand, Viaud and colleagues have shown that ULBP-1 expressed on
the surface of DCs-derived exosomes directly engaged NKG2D and induced NK cell activation [66]. It
is important to consider that NKG2D endocytosis not only leads to reduced cell-surface receptor levels
but also controls signaling outcome in NK cells [67]. Thus, the possibility that exosome-associated
NKG2D ligands could engage NKG2D, thereby triggering intracellular signaling, remains an intriguing
and open question that requires further investigation (Figure 1a).
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Figure 1. Effects of distinct molecules produced by stressed cancer cells on NK cell-mediated
functions. (a) Exosomes expressing NKG2D ligands induce NKG2D downmodulation leading to
an impairment of NKG2D-mediated cytotoxicity. (b) Exosomes expressing HSP70 engage TLR2
expressed on distinct innate immune cell populations as indicated. The direct TLR2 engagement on
NK cells induces cellular activation. In contrast, TLR2 triggering on MDCSs induces the production of
immunosuppressive factors that can impair NK cell activity. (c) Specific miRNAs can engage TLR8
expressed by macrophages leading to inflammatory cytokine production or TLR7 on plasmacytoid
DCs leading to type I IFN production, that in turn contribute to NK cell activation. (d) Double strand
DNA (dsDNA) accumulates in the cytoplasm of cancer cells in response to stress stimuli where it
activates the cGAS/STING pathway leading to type I IFN production; in turn, dsDNA is packaged into
exosomes and released in the tumor microenvironment where it is taken up by DCs that produce type I
IFNs with a mechanism dependent on the cGAS/STING pathway. Type I IFNs, produced either by
stressed cancer cells or DCs, activate NK cell-mediated functions, including cytotoxicity and cytokine
production. “T” means inhibition. NK, Natural Killer; HSP70, Heat shock protein 70; NKG2D, NK
group 2 member D; TLR2, Toll-like receptor 2; MDSCs, Myeloid suppressor cells; IFN, interferon; cGAS,
Cyclic guanosine monophosphate (GMP)-adenosine monophosphate synthase; STING, stimulator of
IFN gene.
4.2. The Heat Shock Protein Family
The heat shock proteins (HSPs) represent a class of chaperones that assist protein folding and
prevent the formation of nonspecific protein aggregates, and are generally localized in intracellular
compartments, such as cytoplasm, endoplasmic reticulum (ER) and mitochondria. HSPs are divide
into five large families acc rding to their molecular weight: HSP110, HSP90, HSP70, HSP60 and
small HSPs [68]. A wide variety of stressful conditions can cause HSP m biliz tion to th plasma
membrane or their rele se from cells, thus acting s potent danger signals. Several pieces of evidence
demonstrate that extracellular-located HSPs can be associated with extracellular vesicles, includi g
exosomes [69–71]. In general, exosomes expressing HSPs have immunostimulatory properties on
NK cell-mediated functions. Notably, colon carcinoma derived HSP70 associated to exosomes
stimulated NK cell migration and cytotoxic activity [72]. It has been de onstrated that the usage
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of anticancer drugs up-regulated the expression of distinct HSPs (e.g., HSP70, HSP60 and HSP90)
on exosomes derived from human hepatocellular carcinoma cell lines. The authors further proved
that HSP+ exosomes induced an increase of NK cell cytotoxic activity [73]. In addition, we have
recently demonstrated that HSP70 on the surface of multiple myeloma-derived exosomes triggers
NK cell-mediated IFN-γ production through a mechanism dependent on the activation of NF-κB
signaling pathway by TLR2 engagement [33]. Of interest, HSP70+ exosomes were isolated from
the bone marrow aspirates derived from multiple myeloma patients making evident that this
class of nanovesicles is present in the tumor microenvironment, thus potentially contributing to
the cross-talk between malignant plasma cells and immune cells [33]. The capability of HSP70
to bind to TLR2 determines the stimulation of other innate immune cell populations including
macrophages, DCs, and myeloid-derived suppressor cells (MDSCs). Chow and colleagues have
proposed a model of TLR2-mediated NF-κB activation and consequent inflammatory cytokine
production in human macrophages in response to breast cancer cell-derived exosomes contributing to
metastatic tumor development [74]. Other studies have reported that HSP70+ Tex are efficacious in
the activation of MDSCs through TLR2 engagement leading to the production of immunosuppressive
cytokines [35,75,76]. On the other hand, some evidence has shown the capacity of HSPs expressing
exosomes to stimulate DCs leading to anti-tumor immune responses in distinct cancer models [77,78].
In this regard, multiple myeloma-derived exosomes overexpressing membrane-bound HSP70 have
the capability to induce DC maturation and stimulate type 1 CD4+ T and CD8+ T-cell responses along
with the induction of NK cell-mediated immunity in mice [77].
Overall, the final outcome of HSP+ exosomes on NK cell anti-tumor immune response depends
on a direct stimulatory effect on these cytotoxic lymphocytes and/or on the different subset of immune
cells localized in the tumor microenvironment and responsive to HSPs (Figure 1b).
4.3. MicroRNAs
MicroRNAs (miRNAs) are a class of small (19–25 nucleotides) non-coding single-stranded
RNA molecules that have emerged as key players in the post-transcriptional regulation of protein
expression and degradation. These small RNAs have been described to be a crucial component
of exosomal cargo [79] and specific sets of miRNAs are enriched into exosomes thanks to specific
molecular sorting mechanisms due to the involvement of RNA binding proteins [80–83]. In this
regard, Villarroya-Beltri and colleagues observed that the sumoylation of the heterogeneous nuclear
ribonucleoprotein A2B1 (hnRNPA2B1) regulates the binding to a miRNA motif, thereby affecting
miRNA exosomal loading [81]. In both mice and humans, miRNAs have been shown to be critical
regulators of NK cell activation, survival and function [84,85]. Cellular stress can strongly affect the
exosomal miRNA cargo. For example, Umezu and colleagues have shown that the amount of miR-135b
associated with multiple myeloma-derived exosomes increased in response to hypoxia [86]. Similarly,
breast cancer cells cultured in hypoxic conditions released EVs carrying miR210 that inhibited NK
cell-mediated functions [87].
In addition to the classical role of miRNAs able to specifically target mRNAs determining their
degradation or the inhibition of their translation, mounting evidence has shown that selected miRNAs
can act as DAMPs by engaging TLRs, thus suggesting an alternative mechanism of innate immune
cell regulation [88–91]. As such, Fabbri and colleagues demonstrated that miR-21 and miR-29a, highly
expressed into lung cancer derived exosomes, can directly bind to TLR8 in human macrophages
thereby causing proinflammatory cytokine production (i.e., IL-6, TNF-α) through the activation of the
NF-κB pathway [88]. Recently, another study has reported that some exosomal miRNAs possessing an
IFN induction motif (IIM), such as miR-574, let-7b and miR-21, can act as endogenous ligands of TLR7,
leading to the activation of plasmacytoid DCs [91].
Altogether, these findings show that miRNAs profile into exosomes can change in response to
stress conditions and in some circumstances, specific miRNAs, through the direct binding to TLRs, act
as danger signals, stimulating innate immune cells (Figure 1c).
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4.4. Cytosolic DNA
In normal conditions DNA is confined to the nucleus and mitochondria; however, in the presence
of DNA damage, DNA accumulates in the cytoplasm where it is detected as a DAMP by a number
of cytosolic sensors that converge on the STING (stimulator of IFN gene) adaptor protein pathway
leading to type I interferon (IFN) expression. Cyclic guanosine monophosphate (GMP)-adenosine
monophosphate synthase (cGAS) represents a key cytosolic sensor able to detect dsDNA into the
cytoplasm [92]. Upon cGAS DNA binding, this enzyme produces a second messenger, the cyclic
2′3′-GMP-AMP (cGAMP) that represents a high affinity ligand for STING [92–94]. Actually, it is
largely unclear how DNA damage leads to DNA accumulation in the cytosol. A number of recent
studies report that nuclear DNA in the cytoplasm can be loaded and stored into exosomes [21,22,95–97].
In general, DNA associated with cancer-derived exosomes is more abundant when compared to healthy
cells [22]. Takahashi and colleagues have demonstrated that the inhibition of exosome secretion results
in the accumulation of nuclear DNA in the cytoplasm, thereby causing the activation of cGAS-STING
pathway leading to type I IFN production [95]. These data indicate that exosome secretion might
maintain cellular homeostasis by removing harmful cytoplasmic DNA from cells. Another recent
study has shown that tumor-derived exosomes produced by irradiated mouse breast cancer cells
transfer dsDNA to DCs and stimulate upregulation of cell surface costimulatory molecules, as well as
the STING-dependent activation of type I IFNs [98]. Similarly, the anti-tumor agent topotecan (TPT),
an inhibitor of topoisomerase I, has been shown to stimulate the release of exosomes containing DNA
from breast cancer cells, thus leading to DC activation via STING signaling [96]. Overall, these findings
show that dsDNA associated with cancer-derived exosomes triggers type I IFN production directly
from cancer cells or indirectly through the DCs stimulation (Figure 1d). Accumulating evidence
suggests that type I IFNs have a crucial role in cancer progression through the promotion of anti-cancer
immune responses [99,100]. In particular, it has been observed that type I IFNs enhanced DC-mediated
cross-presentation of tumor antigens to cytotoxic T lymphocytes [99,101,102]. In addition, type I
IFNs promote DCs to release IL-15, which is important to maintain the survival of CD8+ memory
cells and NK cells [103,104]. Type I IFNs can directly activate NK cell-mediated functions increasing
perforin-dependent cytotoxicity [105] and inducing TRAIL expression; moreover, with the coordinated
action of IL-12, type I IFNs greatly enhance NK cell-mediated IFN-γ production. The possible effects
of dsDNA associated with Tex to modulate NK cell activity is depicted in Figure 1d.
5. Conclusions and Perspectives
The capability of cancer-derived exosomes to carry immunomodulatory molecules represents
a crucial aspect in the anti-tumor immune response, although further studies are necessary to
evaluate the in vivo role of cancer-derived exosomes. Mounting evidence reveals that exosomes
secreted from cancer cells in response to chemotherapeutic treatments and, in general, to stress
conditions, represent important messengers of DAMPs, as well as stress-induced molecules such as
NKG2D ligands. It is still largely unknown whether exosomal-associated NKG2D ligands function
differently from those released through protease-mediated cleavage. Indeed, exosomes transport
simultaneously distinct biologically active molecules that can cooperate to trigger together signals
to the target cell. Furthermore, a better characterization of exosome molecular phenotype and
immunomodulatory properties will provide new insights into their immune-regulatory role during
the course of chemotherapeutic interventions and, possibly, into their use as prognostic biomarkers.
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